Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review

• Published in: Frontiers in immunology Vol. 10; p. 1489
• Main Authors: Leurs, Amélie, Gnemmi, Viviane, Lionet, Arnaud, Renaud, Loïc, Gibier, Jean-Baptiste, Copin, Marie-Christine, Hachulla, Eric, Hatron, Pierre-Yves, Launay, David, Fajgenbaum, David, Terriou, Louis
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers 28.06.2019; Frontiers Media S.A
• Series: Frontiers in Immunology
• Subjects: idiopathic multicentric Castleman disease; Immunology; interleukin-6; Life Sciences; membranoproliferative glomerulonephritis; TAFRO syndrome; thrombotic microangiopathy glomerulopathy; VEGF; TAFRO syndrome; idiopathic multicentric Castleman disease; membranoproliferative glomerulonephritis; thrombotic microangiopathy glomerulopathy; VEGF; interleukin-6
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2019.01489

TAFRO syndrome is a clinical subtype of idiopathic multicentric Castleman disease (iMCD) that is characterized by thrombocytopenia, anasarca, fever and/or elevated serum C-reactive protein, renal dysfunction, and organomegaly. A 28-year-old woman with fever, weight gain of 13 kgs, lower extremity edema, hepatosplenomegaly, and multicentric peripheral lymphadenopathy was referred to our center. Laboratory investigations revealed anemia, thrombocytopenia, creatinine at 1.19 mg/dL and hypoalbuminemia at 33 g/L. Proteinuria was measured at 2 g/day including albuminuria at 1.5 g/day. Urinary sediment examination found leukocyturia at 44,000/mL and hematuria at 645,000/mL. Vascular endothelial growth factor (VEGF) level was elevated. A cervical lymph node biopsy found features consistent with the mixed histopathological subtype of iMCD. A renal biopsy revealed a membranoproliferative glomerulonephritis (MPGN) pattern. We initiated 3 days of methylprednisolone pulse-therapy at 1,000 mg per day, followed by prednisone 1 mg/kg/day and evolution was favorable. 19 iMCD patients with TAFRO syndrome had undergone a renal biopsy: 8 cases with author's diagnosis consistent with MPGN-like and 11 cases of thrombotic microangiopathy (TMA)-like glomerulopathy without fibrin thrombi in glomerular capillaries or arterioles and without typical biological signs. Clinical, biological, and outcome characteristics were similar between the cases described as having MPGN and TMA-like presentation. After a thorough review of histopathological descriptions for each case, MPGN lesions seems to be the consequences of chronic glomerular endothelial injury in persistent TMA. We suspect that VEGF and IL-6 play a key role in the physiopathology of the spectrum of renal involvement from TMA-like to MPGN observed in TAFRO syndrome. We present a Caucasian iMCD patient with TAFRO syndrome with renal insufficiency secondary to MPGN, which might be secondary to a chronic TMA-like disease. We suspect that there is a continuum between TMA and MPGN lesions in TAFRO syndrome favored by VEGF and IL-6.